Commenting on the handover, Scholar Rock chairman David Hallal said that Mahanthappa “has been a remarkable executive, building upon breakthrough academic research to lead Scholar Rock through ...

In a look ahead at a week of Cambridge and Somerville events, there’s a free pi day pie potluck, comedy against cancer, Mobius performance art called “Slay,” Ukrainian folk-rock, a St. Patrick’s fun ...

Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The firm’s 50 day moving average is $39.68 and its 200-day moving average is $31.01.

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have earned an average rating of “Buy” from the seven brokerages that are covering the company, MarketBeat reports.

CAMBRIDGE, Mass., February 25, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Scholar Rock Holding Corporation ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company dedicated to developing treatments for serious diseases, has granted inducement equity awards to seven newly hired ...

Scholar Rock (SRRK) announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy ...

Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company dedicated to developing treatments for serious diseases, has granted inducement equity awards to seven newly hired employees ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...